Linda Kusner, PhD will present new data utilizing MV2C2 antibodies in Myasthenia Gravis. “Survivin is a negative regulator of apoptosis in myasthenia gravis: a human and animal model study” (October 16,…
Clinical-stage biotechnology company also sharing its accomplishments to date and future plans at the 2019 Biotechnology Innovation Organization (BIO) International Convention BUFFALO, N.Y., May 29, 2019 /PRNewswire/ -- MimiVax LLC, a clinical-stage…
Molecule can exist on tumor surface, suggesting new opportunities for CAR T and antibody-based therapies BUFFALO, N.Y. — New research from Roswell Park Comprehensive Cancer Center and MimiVax LLC shows…
Novel immunotherapy, SurVaxM, being developed as treatment for glioblastoma BUFFALO, N.Y. — The U.S. Food and Drug Administration has awarded orphan drug status to a promising immunotherapy vaccine developed at…
Immunotherapy Developed at Roswell Park Being Tested as Treatment for Multiple Myeloma BUFFALO, N.Y. — An immune-based therapy developed at Roswell Park Cancer Institute (RPCI) is moving forward with its…
Phase II clinical trial will assess efficacy of Roswell Park-developed immunotherapy in newly diagnosed patients BUFFALO, N.Y. — An innovative vaccine therapy developed at Roswell Park Cancer Institute (RPCI) is…
Phase I clinical trial results of SurVaxM presented at AACR Annual Meeting 2015 in Philadelphia BUFFALO, N.Y. — A first-of-its kind cancer vaccine, SurVaxM, has demonstrated safety and tolerability in…